TAK-079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion
Glennda Smithson(Takeda (United States)), Kathleen Elias(Ignyta (United States)), Martin E. Dahl(Takeda (United States)), Josh Yuan(Takeda (United States)), Wouter Korver(Allakos (United States)), Lin‐Pierre Zhao, Stefan Roepcke(Takeda (Switzerland)), Lachy McLean(Takeda (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 14
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
|British Journal of Dermatology|2021|414
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403